Morgan Stanley Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $9
Morgan Stanley Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Cuts Target Price to $9
SAGE Therapeutics: Balancing Promising Sales Growth With Strategic Uncertainties – A Hold Rating
Sage Therapeutics Announces Resignation Of Kimi Iguchi From Her Position As CFO And Treasurer Of The Co And From Any And All Other Positions She Holds As An Officer Or Employee Of The Company Or An Officer, Employee Or Director Of Any Of Its Subsidiaries
Express News | Sage Therapeutics: Resignation of Kimi Iguchi From Her Position as CFO of Co
A Quick Look at Today's Ratings for Sage Therapeutics(SAGE.US), With a Forecast Between $10 to $26